Open AccessCharacteristics and Lipid Distribution of a Large, High‐Risk, Hypertensive Population: The Lipid‐Lowering Component of the Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
Author(s) -
Papademetriou Vasilios,
Piller Linda B.,
Ford Charles E.,
Gordon David,
Hartney Thomas J.,
Geraci Therese S.,
Reisin Efrain,
Sumner Brian Montgomery,
Wong Nathan D.,
Nwachuku Chuke,
Narayan Puneet,
Haywood L. Julian,
Habib Gabriel
Publication year - 2003
Publication title -
the journal of clinical hypertension
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 67
eISSN - 1751-7176
pISSN - 1524-6175
DOI - 10.1111/j.1524-6175.2003.03163.x
Subject(s) - medicine , lisinopril , doxazosin , pravastatin , cholesterol , chlorthalidone , body mass index , population , randomized controlled trial , lipoprotein , endocrinology , high density lipoprotein , blood pressure , angiotensin converting enzyme , environmental health
The Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) consisted of 42,418 participants randomized to one of four antihypertensive treatment groups: chlorthalidone, amlodipine, lisinopril, or doxazosin. A subset of these participants with fasting low‐density lipoprotein cholesterol levels 100–189 mg/dL were randomized into a lipid‐lowering component: 5170 to receive pravastatin (40 mg daily) and 5185 to receive usual care. This report describes the characteristics and lipid distribution of these participants. There were no important differences between the randomized treatment groups. Women had higher total cholesterol, low‐density lipoprotein cholesterol, and high‐density lipoprotein cholesterol than men. There was a similar finding for black participants compared with whites, except blacks had lower triglycerides. Diabetics had lower high‐density lipoprotein cholesterol and higher triglycerides than nondiabetics, and patients with body mass index <25 kg/m 2 had higher high‐density lipoprotein cholesterol but lower low‐density lipoprotein cholesterol and triglycerides than patients with higher body mass index. The success of the randomization of this large, diverse population and the differences in the lipid distributions among its subgroups will allow further understanding of optimal lipid‐lowering treatment.